540 related articles for article (PubMed ID: 9811699)
1. Neutralizing antibodies from the sera of human immunodeficiency virus type 1-infected individuals bind to monomeric gp120 and oligomeric gp140.
Stamatos NM; Mascola JR; Kalyanaraman VS; Louder MK; Frampton LM; Birx DL; VanCott TC
J Virol; 1998 Dec; 72(12):9656-67. PubMed ID: 9811699
[TBL] [Abstract][Full Text] [Related]
2. Comparison of HIV Type 1 ADA gp120 monomers versus gp140 trimers as immunogens for the induction of neutralizing antibodies.
Kim M; Qiao ZS; Montefiori DC; Haynes BF; Reinherz EL; Liao HX
AIDS Res Hum Retroviruses; 2005 Jan; 21(1):58-67. PubMed ID: 15665645
[TBL] [Abstract][Full Text] [Related]
3. Characterization of antibody responses elicited by human immunodeficiency virus type 1 primary isolate trimeric and monomeric envelope glycoproteins in selected adjuvants.
Li Y; Svehla K; Mathy NL; Voss G; Mascola JR; Wyatt R
J Virol; 2006 Feb; 80(3):1414-26. PubMed ID: 16415019
[TBL] [Abstract][Full Text] [Related]
4. Screening of HIV-1 Env glycoproteins for the ability to raise neutralizing antibody using DNA immunization and recombinant vaccinia virus boosting.
Richmond JF; Mustafa F; Lu S; Santoro JC; Weng J; O'Connell M; Fenyö EM; Hurwitz JL; Montefiori DC; Robinson HL
Virology; 1997 Apr; 230(2):265-74. PubMed ID: 9143282
[TBL] [Abstract][Full Text] [Related]
5. A comparative immunogenicity study in rabbits of disulfide-stabilized, proteolytically cleaved, soluble trimeric human immunodeficiency virus type 1 gp140, trimeric cleavage-defective gp140 and monomeric gp120.
Beddows S; Franti M; Dey AK; Kirschner M; Iyer SP; Fisch DC; Ketas T; Yuste E; Desrosiers RC; Klasse PJ; Maddon PJ; Olson WC; Moore JP
Virology; 2007 Apr; 360(2):329-40. PubMed ID: 17126869
[TBL] [Abstract][Full Text] [Related]
6. Humoral response to oligomeric human immunodeficiency virus type 1 envelope protein.
Richardson TM; Stryjewski BL; Broder CC; Hoxie JA; Mascola JR; Earl PL; Doms RW
J Virol; 1996 Feb; 70(2):753-62. PubMed ID: 8551612
[TBL] [Abstract][Full Text] [Related]
7. A Trimeric HIV-1 Envelope gp120 Immunogen Induces Potent and Broad Anti-V1V2 Loop Antibodies against HIV-1 in Rabbits and Rhesus Macaques.
Jones AT; Chamcha V; Kesavardhana S; Shen X; Beaumont D; Das R; Wyatt LS; LaBranche CC; Stanfield-Oakley S; Ferrari G; Montefiori DC; Moss B; Tomaras GD; Varadarajan R; Amara RR
J Virol; 2018 Mar; 92(5):. PubMed ID: 29237847
[TBL] [Abstract][Full Text] [Related]
8. HIV-1 Envgp140 trimers elicit neutralizing antibodies without efficient induction of conformational antibodies.
Bower JF; Li Y; Wyatt R; Ross TM
Vaccine; 2006 Jun; 24(26):5442-51. PubMed ID: 16621193
[TBL] [Abstract][Full Text] [Related]
9. The ability of an oligomeric human immunodeficiency virus type 1 (HIV-1) envelope antigen to elicit neutralizing antibodies against primary HIV-1 isolates is improved following partial deletion of the second hypervariable region.
Barnett SW; Lu S; Srivastava I; Cherpelis S; Gettie A; Blanchard J; Wang S; Mboudjeka I; Leung L; Lian Y; Fong A; Buckner C; Ly A; Hilt S; Ulmer J; Wild CT; Mascola JR; Stamatatos L
J Virol; 2001 Jun; 75(12):5526-40. PubMed ID: 11356960
[TBL] [Abstract][Full Text] [Related]
10. The first hypervariable region of the gp120 Env glycoprotein defines the neutralizing susceptibility of heterologous human immunodeficiency virus type 1 isolates to neutralizing antibodies elicited by the SF162gp140 immunogen.
Ching LK; Vlachogiannis G; Bosch KA; Stamatatos L
J Virol; 2008 Jan; 82(2):949-56. PubMed ID: 18003732
[TBL] [Abstract][Full Text] [Related]
11. Conformational Epitope-Specific Broadly Neutralizing Plasma Antibodies Obtained from an HIV-1 Clade C-Infected Elite Neutralizer Mediate Autologous Virus Escape through Mutations in the V1 Loop.
Patil S; Kumar R; Deshpande S; Samal S; Shrivastava T; Boliar S; Bansal M; Chaudhary NK; Srikrishnan AK; Murugavel KG; Solomon S; Simek M; Koff WC; Goyal R; Chakrabarti BK; Bhattacharya J
J Virol; 2016 Jan; 90(7):3446-57. PubMed ID: 26763999
[TBL] [Abstract][Full Text] [Related]
12. Evaluating the immunogenicity of a disulfide-stabilized, cleaved, trimeric form of the envelope glycoprotein complex of human immunodeficiency virus type 1.
Beddows S; Schülke N; Kirschner M; Barnes K; Franti M; Michael E; Ketas T; Sanders RW; Maddon PJ; Olson WC; Moore JP
J Virol; 2005 Jul; 79(14):8812-27. PubMed ID: 15994775
[TBL] [Abstract][Full Text] [Related]
13. Antibodies with specificity to native gp120 and neutralization activity against primary human immunodeficiency virus type 1 isolates elicited by immunization with oligomeric gp160.
VanCott TC; Mascola JR; Kaminski RW; Kalyanaraman V; Hallberg PL; Burnett PR; Ulrich JT; Rechtman DJ; Birx DL
J Virol; 1997 Jun; 71(6):4319-30. PubMed ID: 9151820
[TBL] [Abstract][Full Text] [Related]
14. Characterization of sera from subjects infected with HIV-1 subtypes B and E in Thailand by antibody binding and neutralization.
Louisirirotchanakul S; Beddows S; Cheingsong-Popov R; Shaffer N; Mastro TD; Auewarakul P; Likanonsakul S; Wasi C; Weber J
J Acquir Immune Defic Syndr Hum Retrovirol; 1998 Dec; 19(4):315-20. PubMed ID: 9833739
[TBL] [Abstract][Full Text] [Related]
15. Study of the V3 loop as a target epitope for antibodies involved in the neutralization of primary isolates versus T-cell-line-adapted strains of human immunodeficiency virus type 1.
Spenlehauer C; Saragosti S; Fleury HJ; Kirn A; Aubertin AM; Moog C
J Virol; 1998 Dec; 72(12):9855-64. PubMed ID: 9811721
[TBL] [Abstract][Full Text] [Related]
16. Generation and structural analysis of soluble oligomeric gp140 envelope proteins derived from neutralization-resistant and neutralization-susceptible primary HIV type 1 isolates.
Stamatatos L; Lim M; Cheng-Mayer C
AIDS Res Hum Retroviruses; 2000 Jul; 16(10):981-94. PubMed ID: 10890360
[TBL] [Abstract][Full Text] [Related]
17. Importance of conformation on the neutralizing antibody response to HIV-1 gp120.
Steimer KS; Haigwood NL
Biotechnol Ther; 1991; 2(1-2):63-89. PubMed ID: 1726963
[TBL] [Abstract][Full Text] [Related]
18. Immunogenicity and protective efficacy of oligomeric human immunodeficiency virus type 1 gp140.
Earl PL; Sugiura W; Montefiori DC; Broder CC; Lee SA; Wild C; Lifson J; Moss B
J Virol; 2001 Jan; 75(2):645-53. PubMed ID: 11134278
[TBL] [Abstract][Full Text] [Related]
19. Elicitation of neutralizing antibodies with DNA vaccines expressing soluble stabilized human immunodeficiency virus type 1 envelope glycoprotein trimers conjugated to C3d.
Bower JF; Yang X; Sodroski J; Ross TM
J Virol; 2004 May; 78(9):4710-9. PubMed ID: 15078953
[TBL] [Abstract][Full Text] [Related]
20. Antibody responses elicited in macaques immunized with human immunodeficiency virus type 1 (HIV-1) SF162-derived gp140 envelope immunogens: comparison with those elicited during homologous simian/human immunodeficiency virus SHIVSF162P4 and heterologous HIV-1 infection.
Derby NR; Kraft Z; Kan E; Crooks ET; Barnett SW; Srivastava IK; Binley JM; Stamatatos L
J Virol; 2006 Sep; 80(17):8745-62. PubMed ID: 16912322
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
